Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

Bhattachar SN, Tham LS, Li Y, Chua L, Ng SX, Tang Y, Ibriga H, Ni W, Gurbuz S, Mather KJ, Thomas MK

Diabetes, obesity & metabolism20 Aug 2025Cited by 9 (Europe PMC)

PMID40832785PMCIDPMC12515780DOI10.1111/dom.70040PepBankPUB-40832785

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, improved fasting metabolic biomarker profiles were associated with mazdutide treatment.
In plain wordsIn adults with overweight or obesity, mazdutide treatment was linked to better fasting blood markers of metabolism.
Peptide
Mazdutide
Outcome
Direction not reportedFasting metabolic biomarker profiles
Study
n = 32
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
Improved fasting metabolic biomarker profiles and reduced appetite were associated with mazdutide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278507
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, reduced appetite was associated with mazdutide treatment.
In plain wordsIn adults with overweight or obesity, mazdutide treatment was linked to reduced appetite.
Peptide
Mazdutide
Outcome
DecreaseAppetite
Study
n = 32
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
Improved fasting metabolic biomarker profiles and reduced appetite were associated with mazdutide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278508
03HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity, no serious adverse events were reported with mazdutide up to 16 mg.
In plain wordsIn adults with overweight or obesity, no serious side effects were reported with mazdutide.
Peptide
Mazdutide
Outcome
No significant changeSerious adverse events
Study
n = 32
Outcome group
Adverse events · Whole body
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
No serious adverse events (AEs) were reported
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278509
04HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity, the most common adverse events with mazdutide were mild or moderate gastrointestinal disorders.
In plain wordsIn adults with overweight or obesity, the most common side effects of mazdutide were mild or moderate stomach and bowel problems.
Peptide
Mazdutide
Outcome
Not applicableMost common adverse events
Study
n = 32
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
the most common AEs were mild or moderate gastrointestinal disorders.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278510
05HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, mazdutide escalation regimen 1 reduced body weight at week 20 more than placebo.
In plain wordsIn adults with overweight or obesity, mazdutide in Cohort 1 led to more weight loss than placebo at week 20.
Peptide
Mazdutide
Outcome
DecreaseBody weight percent change at week 20, Cohort 1
Study
n = 20
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Body weight change
−20%
Cohort 1, week 20
Body weight change
−0.1%
placebo, week 20
Source sentences
Summary
At Week 20, mean percent change from baseline in body weight was -20.0% (SE: 1.9) for Cohort 1 and -21.0% (1.2) for Cohort 2 versus -0.1% (1.5) for placebo (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278501
06HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, mazdutide escalation regimen 2 reduced body weight at week 20 more than placebo.
In plain wordsIn adults with overweight or obesity, mazdutide in Cohort 2 led to more weight loss than placebo at week 20.
Peptide
Mazdutide
Outcome
DecreaseBody weight percent change at week 20, Cohort 2
Study
n = 20
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Body weight change
−21%
Cohort 2, week 20
Body weight change
−0.1%
placebo, week 20
Source sentences
Summary
At Week 20, mean percent change from baseline in body weight was -20.0% (SE: 1.9) for Cohort 1 and -21.0% (1.2) for Cohort 2 versus -0.1% (1.5) for placebo (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278502
07HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, mazdutide Cohort 1 reduced waist circumference more than placebo.
In plain wordsIn adults with overweight or obesity, mazdutide in Cohort 1 reduced waist size more than placebo.
Peptide
Mazdutide
Outcome
DecreaseWaist circumference percent change, Cohort 1
Study
n = 20
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Waist circumference change
−12%
Cohort 1
Waist circumference change
−0.8%
placebo
Source sentences
Summary
Mean percent change in waist circumference was -12.0% (SE: 1.7) in Cohort 1 and -17.0% (1.7) in Cohort 2 versus -0.8% (2.1) in placebo (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278505
08HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, mazdutide Cohort 2 reduced waist circumference more than placebo.
In plain wordsIn adults with overweight or obesity, mazdutide in Cohort 2 reduced waist size more than placebo.
Peptide
Mazdutide
Outcome
DecreaseWaist circumference percent change, Cohort 2
Study
n = 20
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Waist circumference change
−17%
Cohort 2
Waist circumference change
−0.8%
placebo
Source sentences
Summary
Mean percent change in waist circumference was -12.0% (SE: 1.7) in Cohort 1 and -17.0% (1.7) in Cohort 2 versus -0.8% (2.1) in placebo (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278506
09HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, 66.7% of Cohort 1 achieved weight loss of at least 15% with mazdutide.
In plain wordsIn adults with overweight or obesity, about two thirds of people in mazdutide Cohort 1 lost at least 15% of body weight.
Peptide
Mazdutide
Outcome
IncreaseWeight loss of at least 15%, Cohort 1
Study
n = 12
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Responders with weight loss >=15%
66.7%
Cohort 1
Source sentences
Summary
Weight loss of ≥15% was achieved by 66.7% of Cohort 1 and 75.0% of Cohort 2.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278503
10HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, 75.0% of Cohort 2 achieved weight loss of at least 15% with mazdutide.
In plain wordsIn adults with overweight or obesity, three quarters of people in mazdutide Cohort 2 lost at least 15% of body weight.
Peptide
Mazdutide
Outcome
IncreaseWeight loss of at least 15%, Cohort 2
Study
n = 12
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 16 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Responders with weight loss >=15%
75%
Cohort 2
Source sentences
Summary
Weight loss of ≥15% was achieved by 66.7% of Cohort 1 and 75.0% of Cohort 2.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous injections of mazdutide (n = 24) or placebo (n = 8) for 20 weeks.
Summary · context
Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16-mg target dose.
Report a problemFND-4083278504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT05623839

A Study of LY3305677 in Participants With Obesity Or Overweight

Eli Lilly and Companyn = 3216 Nov 2022 to 27 Jun 2023

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 5 Jul 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.